# EDGAR Filing Document

**Accession Number:** 0001611241
**File Stem:** 0001193125-23-038884
**Filing Date:** 2023-2
**Character Count:** 8226
**Document Hash:** c4da2b896770ca792b8865098a07aea5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-038884.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001193125-23-038884

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TFF Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001733413
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 824344737
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91311
- **FILM NUMBER:** 23627987

**BUSINESS ADDRESS:**
- **STREET 1:** 2600 VIA FORTUNA, SUITE 360
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78746
- **BUSINESS PHONE:** 737-802-1973

**MAIL ADDRESS:**
- **STREET 1:** 2600 VIA FORTUNA, SUITE 360
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78746
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lung Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001611241
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 461383209
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** P.O. BOX 150183
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78715
- **BUSINESS PHONE:** 512-809-8549

**MAIL ADDRESS:**
- **STREET 1:** P.O. BOX 150183
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78715

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**SCHEDULE 13G** 

**Under the Securities Exchange Act of 1934** 

**(Amendment No. 3)\*** 

------

## TFF Pharmaceuticals, Inc.
**(Name of Issuer)** 

**Common Stock, par value $0.001** 

**(Title of Class of Securities)** 

**87241J104** 

**(CUSIP Number)** 

**12/31/2022** 

**(Date of Event Which Requires Filing of this Statement)** 

------

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;Lung Therapeutics, Inc.<br>&nbsp;&nbsp;&nbsp;&nbsp;I.R.S. IDENTIFICATION NO. OF ABOVE PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;46-1383209 |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC USE ONLY |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>&nbsp;&nbsp;&nbsp;&nbsp;State of Texas |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; NUMBERS OF<br> SHARES<br> &nbsp;&nbsp;&nbsp;&nbsp;BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH: | &nbsp;&nbsp;&nbsp;&nbsp;5 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;773,000 |
| &nbsp;&nbsp;&nbsp; NUMBERS OF<br> SHARES<br> &nbsp;&nbsp;&nbsp;&nbsp;BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH: | 6 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 |
| &nbsp;&nbsp;&nbsp; NUMBERS OF<br> SHARES<br> &nbsp;&nbsp;&nbsp;&nbsp;BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH: | 7 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;773,000 |
| &nbsp;&nbsp;&nbsp; NUMBERS OF<br> SHARES<br> &nbsp;&nbsp;&nbsp;&nbsp;BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH: | 8 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;773,000 |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>&nbsp;&nbsp;&nbsp;&nbsp;2.1% |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;TYPE OF REPORTING PERSON (See Instructions)<br>&nbsp;&nbsp;&nbsp;&nbsp;CO |

---

------

**SCHEDULE 13G** 

**Item 1.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) Name of Issuer:** TFF Pharmaceuticals, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Address of Issuer's Principal Executive Offices:**

1751 River Run, Suite 400

Fort Worth, Texas 76107

**Item 2.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) Name of Person Filing:** Lung Therapeutics, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Address of Principal Business Office or, if None, Residence:**

3801 S. Capital of Texas Hwy, Suite 330 Austin, Texas 78704

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Citizenship:** State of Texas

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d) Title of Class of Securities:** Common Stock, par value $0.001

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e) CUSIP Number:** 87241J104

**Item 3.** 

Not Applicable.

**Item 4. Ownership** 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Amount beneficially owned: 773,000 shares of common stock

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Percent of class: 2.1%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Number of shares as to which such person has:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Sole power to vote or to direct the vote: 773,000

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Shared power to vote or to direct the vote: 0

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Sole power to dispose or to direct the disposition of: 773,000

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Shared power to dispose or to direct the disposition of: 0

------

**Item 5. Ownership of Five Percent or Less of a Class** 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person** 

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company** 

Not applicable.

**Item 8. Identification and Classification of Members of the Group** 

Not applicable.

**Item 9. Notice of Dissolution of Group** 

Not Applicable.

**Item 10. Certifications** 

Not Applicable.

------

**SIGNATURE** 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;February 14, 2023 | &nbsp;&nbsp;&nbsp;&nbsp;February 14, 2023 |
| (Date) | (Date) |
| Lung Therapeutics, Inc. | Lung Therapeutics, Inc. |
| By: | /s/ Brian Windsor |
|  | Name: Brian Windsor |
|  | Title: President and CEO |

---